BioSpace News Archive

Hitachi to Provide CNAO with Proton Therapy System

Hitachi, Ltd. has entered into an agreement to provide Centro Nazionale di Adroterapia Oncologica with its proton therapy system.

December 8, 2019
·
2 min read
BioMidwest

New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Full results are being highlighted today in an oral presentation at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition

December 8, 2019
·
18 min read
Biotech Bay

New Data Demonstrate the Continued Clinical Benefit of Fixed-duration, Chemotherapy-free Venclexta-based Treatments in Chronic Lymphocytic Leukemia

In an updated analysis of the CLL14 study, Venclexta plus Gazyva achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukemia

December 8, 2019
·
27 min read
Pharm Country

Computer Game May Help to Predict Reuse of Opioids

A computer betting game can help predict the likelihood that someone recovering from opioid addiction will reuse the pain-relieving drugs, a new study shows.

December 8, 2019
·
4 min read
Drug Development

Innate Pharma Highlights FDA-Approved Lumoxiti® at ASH 2019Final analysis expands on efficacy results from pivotal Phase III trial of Lumoxiti in hairy cell leukemia; durable, complete responses maintained in long-term follow-up data

Innate Pharma SA shared new, long-term data from the pivotal Phase III trial of Lumoxiti at the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, USA, which expands on the efficacy results and affirms the manageable safety profile of the medicine.

December 8, 2019
·
7 min read
Drug Development

Ziopharm Oncology Presents Pre-Clinical Data Validating “Rapid Personalized Manufacture” (RPM) with TCR at the 2019 American Society for Hematology Annual Meeting

Membrane bound IL-15 (mbIL15) improves anti-tumor effect of TCR-modified T cells

December 8, 2019
·
5 min read
Pharm Country

TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition

100% overall response rate (ORR) in relapsed/refractory CLL patients treated with U2 (umbralisib + ublituximab) plus venetoclax at cycle 7 (n=13)

December 8, 2019
·
7 min read
Drug Development

Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis Showing Activity at All Dose Levels Tested

Plan to initiate screening in registration-enabling portion of PIONEER trial in indolent SM in first half 2020

December 8, 2019
·
14 min read
Drug Development

Oncopeptides Presents Promising Data from the Phase 2 ANCHOR Combination Study in Patients With RRMM at ASH Annual Meeting 2019

Oncopeptides AB will present updated data from the ongoing Phase 2 ANCHOR triple combination study at the ASH Annual Meeting 2019.

December 8, 2019
·
5 min read
Biotech Beach

Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma

December 8, 2019
·
9 min read